Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHA: 603392)
China
· Delayed Price · Currency is CNY 68.47
-0.75 (-1.08%)
Sep 6, 2024, 3:00 PM CST
Beijing Wantai Biological Pharmacy Enterprise Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 2,696 | 5,493 | 11,167 | 5,702 | 2,337 | 1,152 | Upgrade
|
| Other Revenue | 17.27 | 17.3 | 18.52 | 48.34 | 17.14 | 31.71 | Upgrade
|
| Revenue | 2,713 | 5,511 | 11,185 | 5,750 | 2,354 | 1,184 | Upgrade
|
| Revenue Growth (YoY) | -71.19% | -50.73% | 94.51% | 144.25% | 98.88% | 20.46% | Upgrade
|
| Cost of Revenue | 946.77 | 1,002 | 1,198 | 850.67 | 473.6 | 350.41 | Upgrade
|
| Gross Profit | 1,766 | 4,508 | 9,987 | 4,900 | 1,881 | 833.34 | Upgrade
|
| Selling, General & Admin | 1,034 | 1,959 | 3,490 | 1,874 | 810.21 | 506.9 | Upgrade
|
| Research & Development | 1,188 | 1,177 | 1,091 | 677.42 | 309.13 | 163.59 | Upgrade
|
| Other Operating Expenses | 69.94 | 31.57 | 51.28 | 26.71 | 12.51 | 9.25 | Upgrade
|
| Operating Expenses | 2,253 | 3,144 | 4,723 | 2,662 | 1,156 | 683.99 | Upgrade
|
| Operating Income | -486.3 | 1,364 | 5,265 | 2,238 | 724.74 | 149.35 | Upgrade
|
| Interest Expense | -6.16 | -6.86 | -7.67 | -5.69 | -1.69 | -1.04 | Upgrade
|
| Interest & Investment Income | 217.96 | 186.88 | 78.26 | 21 | 18.58 | 22.25 | Upgrade
|
| Currency Exchange Gain (Loss) | 3.14 | 13.01 | 27.89 | -8.75 | -14.29 | 0.38 | Upgrade
|
| Other Non Operating Income (Expenses) | -0.86 | -1.87 | -1 | 0.05 | -0.79 | -0.59 | Upgrade
|
| EBT Excluding Unusual Items | -272.22 | 1,555 | 5,362 | 2,244 | 726.55 | 170.35 | Upgrade
|
| Gain (Loss) on Sale of Investments | 20.91 | 24.66 | 9.98 | 0.03 | 0.35 | 0.2 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.69 | -1.08 | -2.74 | -0.97 | 0.42 | -1.47 | Upgrade
|
| Asset Writedown | -259.15 | -259.15 | - | - | - | - | Upgrade
|
| Other Unusual Items | 228.05 | 73.7 | 213.42 | 80.85 | 37.13 | 47.73 | Upgrade
|
| Pretax Income | -283.12 | 1,393 | 5,583 | 2,324 | 764.45 | 216.81 | Upgrade
|
| Income Tax Expense | -83.89 | 146.89 | 719.39 | 244.93 | 82.64 | 6.51 | Upgrade
|
| Earnings From Continuing Operations | -199.23 | 1,247 | 4,863 | 2,079 | 681.82 | 210.3 | Upgrade
|
| Minority Interest in Earnings | 5.03 | 1.18 | -127.51 | -57.75 | -4.82 | -1.44 | Upgrade
|
| Net Income | -194.2 | 1,248 | 4,736 | 2,021 | 677 | 208.86 | Upgrade
|
| Net Income to Common | -194.2 | 1,248 | 4,736 | 2,021 | 677 | 208.86 | Upgrade
|
| Net Income Growth | - | -73.65% | 134.28% | 198.59% | 224.13% | -28.73% | Upgrade
|
| Shares Outstanding (Basic) | 1,245 | 1,260 | 1,250 | 1,230 | 1,195 | 1,099 | Upgrade
|
| Shares Outstanding (Diluted) | 1,245 | 1,260 | 1,250 | 1,230 | 1,195 | 1,099 | Upgrade
|
| Shares Change (YoY) | -1.94% | 0.86% | 1.55% | 2.96% | 8.71% | 2.96% | Upgrade
|
| EPS (Basic) | -0.16 | 0.99 | 3.79 | 1.64 | 0.57 | 0.19 | Upgrade
|
| EPS (Diluted) | -0.16 | 0.99 | 3.79 | 1.64 | 0.57 | 0.19 | Upgrade
|
| EPS Growth | - | -73.88% | 130.69% | 190.01% | 198.16% | -30.78% | Upgrade
|
| Free Cash Flow | 492 | 378.15 | 3,203 | 634.16 | 77.77 | 110.68 | Upgrade
|
| Free Cash Flow Per Share | 0.40 | 0.30 | 2.56 | 0.52 | 0.07 | 0.10 | Upgrade
|
| Dividend Per Share | 0.320 | 0.320 | 0.714 | 0.099 | 0.088 | - | Upgrade
|
| Dividend Growth | -55.20% | -55.20% | 624.44% | 12.05% | - | - | Upgrade
|
| Gross Margin | 65.10% | 81.81% | 89.29% | 85.21% | 79.88% | 70.40% | Upgrade
|
| Operating Margin | -17.92% | 24.75% | 47.07% | 38.91% | 30.78% | 12.62% | Upgrade
|
| Profit Margin | -7.16% | 22.64% | 42.34% | 35.15% | 28.76% | 17.64% | Upgrade
|
| Free Cash Flow Margin | 18.13% | 6.86% | 28.63% | 11.03% | 3.30% | 9.35% | Upgrade
|
| EBITDA | -252.99 | 1,572 | 5,401 | 2,334 | 809.21 | 229.86 | Upgrade
|
| EBITDA Margin | -9.32% | 28.53% | 48.28% | 40.59% | 34.37% | 19.42% | Upgrade
|
| D&A For EBITDA | 233.31 | 207.98 | 136.17 | 96.2 | 84.47 | 80.51 | Upgrade
|
| EBIT | -486.3 | 1,364 | 5,265 | 2,238 | 724.74 | 149.35 | Upgrade
|
| EBIT Margin | -17.92% | 24.75% | 47.07% | 38.91% | 30.78% | 12.62% | Upgrade
|
| Effective Tax Rate | - | 10.54% | 12.89% | 10.54% | 10.81% | 3.00% | Upgrade
|
| Revenue as Reported | 2,713 | 5,511 | 11,185 | 5,750 | 2,354 | 1,184 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.